R&D Blueprint and COVID-19

                                The current COVID-19 pandemic is unprecedented, but the global response draws on the lessons learned from other disease outbreaks over the past several decades.

                                As part of WHO’s response, the R&D Blueprint was activated to accelerate diagnostics, vaccines and therapeutics for this novel coronavirus. The Blueprint aims to improve coordination between scientists and global health professionals, accelerate the research and development process, and develop new norms and standards to learn from and improve upon the global response.

                                On 30 January 2020, following the recommendations of the Emergency Committee, the WHO Director-General declared that the outbreak constitutes a Public Health Emergency of International Concern (PHEIC).

                                World scientists on COVID-19 then met at the World Health Organization’s Geneva headquarters on 11–12 February 2020 to assess the current level of knowledge about the new virus, agree on critical research questions that need to be answered urgently, and to find ways to work together to accelerate and fund priority research to curtail this outbreak and prepare for those in the future.

                                The discussion led to an agreement on two main goals. The first was to accelerate innovative research to help contain the spread of the epidemic and facilitate care for those affected. The second was to support research priorities that contribute to global research platforms in hopes of learning from the current pandemic response to better prepare for the next unforeseen epidemic.

                                Building on the response to recent outbreaks of Ebola virus disease, SARS-CoV and MERS-CoV, the R&D Blueprint has facilitated a coordinated and accelerated response to COVID-19, including an unprecedented program to develop a vaccine, research into potential pharmaceutical treatments and strengthened channels for information sharing between countries.

                                Vaccines

                                Expert groups


                                 

                                Achievements


                                 

                                Reports


                                Studies per country, showing study design, type of vaccine, study phase and type of patients.

                                Disclaimer on third-party websites*

                                Therapeutics

                                Reports



                                2 December 2020

                                WHO Target Product Profiles for COVID-19 Therapeutics for non-hospitalized patients

                                29 July 2020

                                WHO target product profiles for COVID-19 therapeutics

                                19 June 2020

                                Informal consultation on the potential inclusion of Sofosbuvir/Daclatasvir in a clinical trial - 19 June 2020

                                13 May 2020

                                Informal consultation on the potential inclusion of Immunomodulators in a clinical trial - 13 May 2020

                                8 May 2020

                                Informal consultation on the dose of chloroquine and hydroxychloroquine for the SOLIDARITY Clinical Trial - 8 April 2020

                                7 May 2020

                                Clinical Trial Design Working Group – consultation on immunomodulators - 7th May 2020

                                6 May 2020

                                Informal consultation on the potential inclusion of Immunomodulators in a clinical trial - 6 May 2020

                                1 May 2020

                                Informal consultation on the role of therapeutics in COVID-19 prophylaxis and post-exposure prophylaxis - 1 May 2020

                                16 April 2020

                                Informal consultation on the role of therapeutics in COVID-19 prophylaxis and post-exposure prophylaxis - 16 April 2020

                                15 April 2020

                                Informal consultation on the role of therapeutics in COVID-19 prophylaxis and post-exposure prophylaxis - 15 April 2020

                                11 April 2020

                                Informal consultation on the potential role of interleukin-6 blockers in the clinical management of COVID-19 infection -  11th April 2020

                                10 April 2020

                                Informal consultation on the role of therapeutics in COVID-19 prophylaxis and post-exposure prophylaxis - 10 April 2020

                                Ethics

                                Social Science

                                Meetings

                                * Disclaimer

                                This website and/or database of the World Health Organization (collectively “WHO Site”) may contain links to websites, databases and/or materials developed, sponsored or maintained by third parties unaffiliated with the World Health Organization (collectively, “Third Party Sites”).

                                The World Health Organization (WHO) provides links to Third Party Sites solely as a convenience to users of this WHO Site.  WHO makes no (and hereby disclaims any) representations, warranties or guarantees of any kind (whether express or implied) as to—and shall have no liability whatsoever arising from—any links, Third Party Sites and/or any content provided therein or accessible therefrom, including, without limitation, any representations, warranties or guarantees as to the non-infringement, fitness for a particular purpose, accuracy, completeness, subject matter, timeliness or quality of any Third Party Site or any content provided therein or accessible therefrom, and/or the use of any information (including, without limitation, personal information) that you provide to any such Third Party Sites.

                                The inclusion of links to any Third Party Sites shall not create any liability for WHO arising from or relating to any such links, Third Party Sites and/or any content provided therein or accessible therefrom; and your use of any and all of the foregoing is entirely at your own risk and responsibility. Accordingly, you forever hold WHO harmless from any and all claims, liabilities and/or obligations of any kind arising from or in connection with the use of any such links, Third Party Sites and/or content provided therein or accessible therefrom.

                                WHO reserves the right, in its sole discretion, to discontinue links to any Third Party Sites at any time for any reason. Should you leave the WHO Site via a link contained herein, the content you view in any Third Party Site is not provided or controlled by WHO. The inclusion on this WHO Site of a link to any Third Party Site does not constitute, and shall not be construed as, an endorsement, approval or recommendation by WHO of such Third Party Site and/or of any content, goods or services provided thereon or accessible therefrom.